In addition, Prosonix aims to establish a limited number of co-development partnerships with companies focused on the development of inhaled drugs for respiratory and other indications. These collaborations will enable the Company to leverage its platform beyond its in-house pipeline and to benefit from a share of profits from sales of successful products.

For more information on out-licensing or co-development opportunities, please contact:

Cécile Miles, Chief Business Officer

Email here
Tel: +44 (0)1865 784250